Anti-Human IFN-alpha/beta R1 Reference Antibody (Anifrolumab, RUO)
- Catalog number: BS10301
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Anifrolumab (BS10301) is a research-grade recombinant antibody targeting Interferon alpha/beta receptor 1. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Interferonalpha/betareceptor1,Cytokinereceptorfamily2member1,Cytokinereceptorclass-IImember1,CRF2-1,IFN-R-1,IFNAR1,IFNAR,IFN-alpha/betareceptor1,TypeIinterferonreceptor1
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: MDX-1333,MEDI-546,CAS:1326232-46-5
Background: Interferon alpha/beta receptor 1 (IFNAR1) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes.
References:
1. Russell-Harde, D. et al. (1999) Biochemical and biophysical research communications 255, 539-44. PMID: 10049744
2. Kumar, KG. et al. (2003) The EMBO journal 22, 5480-90. PMID: 1453212
3. Kumar, KG. et al. (2004) The Journal of biological chemistry 279, 46614-20. PMID: 1533777
4. Uzé, G. et al. (1990) Cell 60, 225-34. PMID: 2153461
5. Thomas, C. et al. (2011) Cell 146, 621-32. PMID: 21854986
6. Zheng, H. et al. (2013) Cell reports 5, 180-93. PMID: 24075985
7. Hernandez, N. et al. (2019) The Journal of experimental medicine 216, 2057-2070. PMID: 31270247
8. Gothe, F. et al. (2022) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 74, 136-139. PMID: 33252644
9. Bastard, P. et al. (2022) The Journal of experimental medicine 219. PMID: 35442418
10. Abramovich, C. et al. (1994) The EMBO journal 13, 5871-7. PMID: 7813427
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Interferonalpha/betareceptor1,Cytokinereceptorfamily2member1,Cytokinereceptorclass-IImember1,CRF2-1,IFN-R-1,IFNAR1,IFNAR,IFN-alpha/betareceptor1,TypeIinterferonreceptor1
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: MDX-1333,MEDI-546,CAS:1326232-46-5
Background: Interferon alpha/beta receptor 1 (IFNAR1) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes.
References:
1. Russell-Harde, D. et al. (1999) Biochemical and biophysical research communications 255, 539-44. PMID: 10049744
2. Kumar, KG. et al. (2003) The EMBO journal 22, 5480-90. PMID: 1453212
3. Kumar, KG. et al. (2004) The Journal of biological chemistry 279, 46614-20. PMID: 1533777
4. Uzé, G. et al. (1990) Cell 60, 225-34. PMID: 2153461
5. Thomas, C. et al. (2011) Cell 146, 621-32. PMID: 21854986
6. Zheng, H. et al. (2013) Cell reports 5, 180-93. PMID: 24075985
7. Hernandez, N. et al. (2019) The Journal of experimental medicine 216, 2057-2070. PMID: 31270247
8. Gothe, F. et al. (2022) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 74, 136-139. PMID: 33252644
9. Bastard, P. et al. (2022) The Journal of experimental medicine 219. PMID: 35442418
10. Abramovich, C. et al. (1994) The EMBO journal 13, 5871-7. PMID: 7813427
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
BioactivitySEC-HPLC detection for Research Grade Anifrolumab.
-
SDS-PAGESDS-PAGE for Research Grade Anifrolumab.
-
Western blot
